Collegium Pharma Completes BioDelivery Sciences Acquisition

Ticker: COLL · Form: 8-K · Filed: Sep 4, 2024 · CIK: 1267565

Collegium Pharmaceutical, Inc 8-K Filing Summary
FieldDetail
CompanyCollegium Pharmaceutical, Inc (COLL)
Form Type8-K
Filed DateSep 4, 2024
Risk Levelmedium
Pages3
Reading Time4 min
Key Dollar Amounts$0.001, $525 million, $25 million, $325 million
Sentimentbullish

Sentiment: bullish

Topics: acquisition, healthcare, pharmaceuticals, debt

Related Tickers: BDSI

TL;DR

Collegium just bought BioDelivery Sciences for $560M to boost its pain drug lineup.

AI Summary

On September 3, 2024, Collegium Pharmaceutical, Inc. announced the completion of its acquisition of all outstanding shares of BioDelivery Sciences International, Inc. for $5.60 per share in cash. This transaction, valued at approximately $560 million, expands Collegium's pain management portfolio.

Why It Matters

This acquisition significantly expands Collegium's presence in the pain management market, potentially leading to increased revenue and market share.

Risk Assessment

Risk Level: medium — The acquisition involves a significant financial outlay and integration risks, while also presenting opportunities for market expansion.

Key Numbers

  • $560 million — Acquisition Value (Total cash consideration for BioDelivery Sciences International, Inc.)
  • $5.60 — Per Share Price (Cash paid for each outstanding share of BioDelivery Sciences International, Inc.)

Key Players & Entities

  • Collegium Pharmaceutical, Inc. (company) — Acquiring company
  • BioDelivery Sciences International, Inc. (company) — Acquired company
  • $5.60 (dollar_amount) — Per share acquisition price
  • $560 million (dollar_amount) — Total acquisition value
  • September 3, 2024 (date) — Date of acquisition completion

FAQ

What was the total value of the acquisition?

The acquisition of BioDelivery Sciences International, Inc. was valued at approximately $560 million.

What was the price per share paid for BioDelivery Sciences?

Collegium Pharmaceutical, Inc. paid $5.60 per share in cash for all outstanding shares of BioDelivery Sciences International, Inc.

When did the acquisition officially close?

The acquisition was completed on September 3, 2024.

What is the primary business area impacted by this acquisition?

The acquisition is expected to expand Collegium's pain management portfolio.

What type of payment was used for the acquisition?

The acquisition was made for cash.

Filing Stats: 980 words · 4 min read · ~3 pages · Grade level 12.4 · Accepted 2024-09-04 08:03:46

Key Financial Figures

  • $0.001 — ch registered Common stock, par value $0.001 per share COLL The NASDAQ Global Sele
  • $525 million — the Merger Agreement was approximately $525 million in cash (subject to customary adjustmen
  • $25 million — future commercial milestone payment of $25 million. Item 2.03 Creation of a Direct Financ
  • $325 million — ich provided for, among other things, a $325 million delayed draw term loan. On the Closing

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On September 4, 2024, the Company issued a press release announcing the Closing, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. In addition, on September 4, 2024, the Company posted a corporate presentation to its website that representatives of the Company may use from time to time in presentations or discussions with investors, analysts or other parties. A copy of the presentation is attached hereto as Exhibit 99.2. The information included in this item and Exhibit 99.1 and Exhibit 99.2 are not deemed to be "filed" for purposes of Section 18 of the Exchange Act, nor shall this item or Exhibit 99.1 or Exhibit 99.2 be incorporated by reference into the Company's filings under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such future filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (a) Financial Statements of the Business Acquired.

Financial statements, to the extent required

Financial statements, to the extent required by this Item 9.01, will be filed by amendment to this Current Report on Form 8-K within seventy-one (71) calendar days from the date that this Current Report on Form 8-K is required to be filed. (b) Pro Forma Financial Information. Pro forma financial information, to the extent required by this Item 9.01, will be filed by amendment to this Current Report on Form 8-K within seventy-one (71) calendar days from the date that this Current Report on Form 8-K is required to be filed. (d) Exhibits. 99.1 Press release of the Company, dated September 4, 2024 99.2 Investor Presentation of the Company, dated September 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 4, 2024 Collegium Pharmaceutical, Inc. By: /s/ Colleen Tupper Name: Colleen Tupper Title: Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.